HTG Investment Advisors’s AbbVie ABBV Stock Holding History

HTG Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$213K	Buy	979 +5	+0.5%	+$1.11K	0.06%	80
2025 Q4	$223K	Hold	974	–	–	0.07%	72
2025 Q3	$226K	Buy	+974	New	+$198K	0.08%	70
2025 Q2	–	Sell	-974	Closed	-$204K	–	71
2025 Q1	$204K	Buy	+974	New	+$189K	0.09%	68
2024 Q4	–	Sell	-1,050	Closed	-$207K	–	66
2024 Q3	$207K	Buy	+1,050	New	+$196K	0.1%	63

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HTG Investment Advisors's ABBV Position: Q1 2026 in Review

HTG Investment Advisors increased its AbbVie (ABBV) stake by 0.51% in Q1 2026, buying an estimated $1.11K and bringing the position to 979 shares worth $213K. The position accounts for 0.06% of the portfolio, ranked #80.

HTG Investment Advisors first reported a position in ABBV in Q3 2024 and has held it in 5 quarters since. The position peaked at $226K in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

HTG Investment Advisors held 979 shares of AbbVie worth $213K as of Q1 2026.
HTG Investment Advisors bought 5 AbbVie shares in Q1 2026, an estimated $1.11K.
AbbVie made up 0.06% of HTG Investment Advisors's portfolio in Q1 2026, its #80 holding.
HTG Investment Advisors first reported a position in AbbVie in Q3 2024 and has held it in 5 quarters since.
HTG Investment Advisors's AbbVie position peaked at $226K in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on HTG Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.